Universal screening methods and applications of ThermoFluor®

被引:135
作者
Cummings, Maxwell D. [1 ]
Farnum, Michael A. [1 ]
Nelen, Marina I. [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Exton, PA 19341 USA
关键词
ThermoFluor (R); genomic sequencing; drug discovery;
D O I
10.1177/1087057106292746
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The genomics revolution has unveiled a wealth of poorly characterized proteins. Scientists are often able to produce milligram quantities of proteins for which function is unknown or hypothetical, based only on very distant sequence homology. Broadly applicable tools for functional characterization are essential to the illumination of these orphan proteins. An additional challenge is the direct detection of inhibitors of protein-protein interactions (and allosteric effectors). Both of these research problems are relevant to, among other things, the challenge of finding and validating new protein targets for drug action. Screening collections of small molecules has long been used in the pharmaceutical industry as 1 method of discovering drug leads. Screening in this context typically involves a function-based assay. Given a sufficient quantity of a protein of interest, significant effort may still be required for functional characterization, assay development, and assay configuration for screening. Increasingly, techniques are being reported that facilitate screening for specific ligands for a protein of unknown function. Such techniques also allow for function-independent screening with better characterized proteins. ThermoFluor (R), a screening instrument based on monitoring ligand effects on temperature-dependent protein unfolding, can be applied when protein function is unknown. This technology has proven useful in the decryption of an essential bacterial enzyme and in the discovery of a series of inhibitors of a cancer-related, protein-protein interaction. The authors review some of the tools relevant to these research problems in drug discovery, and describe our experiences with 2 different proteins.
引用
收藏
页码:854 / 863
页数:10
相关论文
共 79 条
[41]   SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands [J].
Muckenschnabel, I ;
Falchetto, R ;
Mayr, LM ;
Filipuzzi, I .
ANALYTICAL BIOCHEMISTRY, 2004, 324 (02) :241-249
[42]  
NELEN B, 2004, 10 ANN C SOC BIOM SC
[43]   Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase:: A 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzyme [J].
Noland, BW ;
Newman, JM ;
Hendle, J ;
Badger, J ;
Christopher, JA ;
Tresser, J ;
Buchanan, MD ;
Wright, TA ;
Rutter, ME ;
Sanderson, WE ;
Müller-Dieckmann, HJ ;
Gajiwala, KS ;
Buchanan, SG .
STRUCTURE, 2002, 10 (11) :1569-1580
[44]   Emerging classes of protein-protein interaction inhibitors and new tools for their development [J].
Pagliaro, L ;
Felding, J ;
Audouze, K ;
Nielsen, SJ ;
Terry, RB ;
Krog-Jensen, C ;
Butcher, S .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (04) :442-449
[45]  
Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1177/108705710100600609
[46]  
PANTOLIANO MW, 2002, Patent No. 20020168686
[47]   1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR [J].
Parks, DJ ;
LaFrance, LV ;
Calvo, RR ;
Milkiewicz, KL ;
Gupta, V ;
Lattanze, J ;
Ramachandren, K ;
Carver, TE ;
Petrella, EC ;
Cummings, MD ;
Maguire, D ;
Grasberger, BL ;
Lu, TB .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) :765-770
[48]   NMR in drug discovery [J].
Pellecchia, M ;
Sem, DS ;
Wüthrich, K .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (03) :211-219
[49]  
Pierceall William E, 2004, Methods Mol Biol, V261, P187
[50]   High-throughput screening assay for the tunable selection of protein ligands [J].
Powell, KD ;
Fitzgerald, MC .
JOURNAL OF COMBINATORIAL CHEMISTRY, 2004, 6 (02) :262-269